Browsing Tag
Zasocitinib
2 posts
Takeda (NYSE: TAK) boosts psoriasis ambitions as Phase 3 zasocitinib data sharpen oral TYK2 challenge
Takeda’s Phase 3 zasocitinib psoriasis data could reshape the oral TYK2 race. Read what it means for Takeda, rivals, and the market now.
Zasocitinib meets all endpoints in Phase 3 trials, Takeda (NYSE: TAK) eyes FDA submission in 2026
Takeda’s once-daily TYK2 pill hits PASI 100 in Phase 3 psoriasis trials. Find out what this means for rivals, regulators, and Takeda’s pipeline strategy.